Device Trial Radar · NCT04453020
Deep Brain Stimulation Effects in Patients With Chronic Refractory Obesity
Last checked: Nov 20, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Feb 7, 2022
Primary completion
Nov 1, 2024
Study completion Nov 1, 2024
Sponsor
- Lead sponsor
- donald whitingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boston Scientific Corporation
- First posted
- Jul 1, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pilot study to evaluate the safety and efficacy of deep brain stimulation (DBS) of the lateral hypothalamic area (LHA) as a treatment for chronic refractory obesity. This study will include 6 individuals with chronic refractory obesity, that have failed other treatments including gastric bypass surgery.
Conditions
- Obesity
Interventions
DBS of the LHADevice
Deep Brain Stimulation of the Lateral Hypothalamic Area
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Complication RatesTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Allegheny General Hospital
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.